Resources

Nurse’s guide to IXEMPRA therapy

This practical guide includes dosing calculations for preparing IXEMPRA® (ixabepilone) for infusion, a review of indications/contraindications, and tables that summarize dose modifications for toxicities and special populations.

Dosing and administration guide

Use this brochure as a quick guide for dosing and administration of IXEMPRA monotherapy and combination therapy with capecitabine.

Pharmacy fact sheet

For a reference for how IXEMPRA is supplied (the 15-mg and 45-mg IXEMPRA Kits), use this pharmacy fact sheet, which includes recommended dosing, premedication, and dose modifications for toxicities and special populations.

Patient brochure

This brochure explains to patients what to expect while being treated with IXEMPRA. This resource lists the indications for IXEMPRA and describes the signs and symptoms of common side effects and the more serious adverse reactions, including peripheral neuropathy, neutropenia, and hypersensitivity.

Study 046: Combination therapy

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Portions of this journal article may contain information not included in the approved IXEMPRA labeling.

Study 081: Monotherapy

Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. Portions of this journal article may contain information not included in the approved IXEMPRA labeling.

IXEMPRA combination speaker program deck

View this educational slide deck, which includes an overview of breast cancer and factors associated with poor prognosis, as well as the clinical data for IXEMPRA combination therapy.

IXEMPRA monotherapy speaker program deck

View this educational slide deck, which includes IXEMPRA indications and usage and the clinical data for its use as monotherapy.

Prescriber perspectives

Solving for Treatment Resistance in Metastatic or Locally Advanced Breast Cancer

Play Video

IXEMPRA (Ixabepilone) for advanced triple-negative breast cancer

Play Video

Clinical activity with evolved disease

Play Video

Managing toxicities associated with IXEMPRA

Play Video

Ideal patients for IXEMPRA

Play Video

Indications and Important Safety Informationexpand

Important Safety Information
WARNING: Toxicity in hepatic impairment

Contraindications

Peripheral neuropathy

Myelosuppression

Hypersensitivity reaction

Pregnancy

Cardiac adverse reactions

Potential for cognitive impairment from excipients

Adverse reactions

Monotherapy

Combination with capecitabine

Cremophor is a registered trademark of BASF AG.

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; CTC = common terminology criteria.

Indications

IXEMPRA® (ixabepilone) is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

  • Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting
  • Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting

IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

Please see US Full Prescribing Information, including boxed WARNING regarding hepatic impairment.

Medical information

For product information or to report an adverse reaction, please call 1-844-586-8953 or e-mail DrugSafety@propharmagroup.com.

This site is intended for US healthcare professionals.

The R-Pharm US Access and Support logo is a trademark and IXEMPRA® is a registered trademark of R-Pharm US Operating LLC, a wholly owned subsidiary of R-Pharm US LLC.

© 2021, R-PHARM US. All rights reserved. IXE-00096-02   08/16

Please verify if you are a US healthcare professional